Chat with us, powered by LiveChat

FDA approves Boehringer Ingelheim Corporation’s Mirapex for the treatment of Parkinson’s disease

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has approved Mirapex ER® extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson’s disease (PD).

MIRAPEX ER is not indicated in advanced PD. Parkinson’s disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.

“MIRAPEX ER for early Parkinson’s disease is a positive development in the treatment of this disease. This new, once-daily treatment has a more convenient dosing schedule, offering greater flexibility as someone with early Parkinson’s disease plans his or her day,” said Robert Hauser, M.D., professor of Neurology, and director, Parkinson’s Disease & Movement Disorders Center at the University of South Florida College of Medicine. “In general, patients often prefer once-daily dosing to a more frequent regimen because of convenience.”